Q32 Bio Inc.
Quick facts
Phase 2 pipeline
- ADX-914 · Oncology
ADX-914 is a monoclonal antibody targeting CD47.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies